Product(s) used in this publication: Peptide ELISA
A vaccination regimen capable of eliciting potent and broadly neutralizing antibodies (bNAbs) remains an unachieved goal of the HIV-1 vaccine field. Here we report the immunogenicity of longitudinal prime/boost vaccination regimens over a period of 200 weeks in guinea pigs with a panel of HIV-1 envelope (Env) gp140 protein immunogens. We assessed vaccine regimens that included a monovalent clade C gp140 regimen (C97), a tetravalent regimen consisting of four clade C gp140s (4C), and a tetravalent regimen consisting of a clade A, B, C, and mosaic gp140 (ABCM). We found that the 4C and ABCM prime/boost regimens were capable of eliciting a greater magnitude and breadth of binding antibodies targeting variable loop 2 (V2) over time, compared to the monovalent C97 only regimen. The longitudinal boosting regimen conducted over more than two years increased the magnitude of certain tier 1 NAbs, but did not increase the magnitude or breadth of heterologous tier 2 NAbs. These data suggest that additional immunogen design strategies are needed to induce broad, high titer tier 2 NAbs.
The elicitation of potent, broadly neutralizing antibodies (bNAbs) remains an elusive goal for the HIV-1 vaccine field. In this study we explored the use of a long-term vaccination regimen with differing immunogens to determine if we could elicit bNAbs in guinea pigs. We found that longitudinal boosting over more than two years increased tier 1 NAbs but did not increase the magnitude and breadth of tier 2 NAbs. These data suggest that additional immunogen designs and vaccination strategies will be necessary to induce broad tier 2 NAb responses.